Population pharmacokinetics of micafungin in neonates and young infants

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2633-2637

  Hope, William W ^a   Smith, P Brian ^b   Arrieta, Antonio ^c   Buell, Donald N ^d   Roy, Michael ^d   Kaibara, Atsunori ^d   Walsh, Thomas J ^e   Cohen Wolkowiez, Michael ^b   Benjamin Jr , Daniel K ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN;

ALLOMETRY; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANDIDA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INFUSION; DRUG POTENCY; DRUG SAFETY; HEMATOGENOUS CANDIDA MENINGOENCEPHALITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MENINGOENCEPHALITIS; MONTE CARLO METHOD; NEWBORN; PREMATURITY; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BAYES THEOREM; CANDIDIASIS; ECHINOCANDINS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LIPOPEPTIDES; MENINGOENCEPHALITIS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; SYNDROME;

EID: 77952633470     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01679-09     Document Type: Article

References (21)

1. Benjamin, D. K., Jr., C. Poole, W. J. Steinbach, J. L. Rowen, and T. J. Walsh. 2003. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 112:634-640.
2. Benjamin, D. K., Jr., P. B. Smith, A. Arrieta, L. Castro, P. J. Sanchez, D. Kaufman, L. J. Arnold, L. L. Kovanda, T. Sawamoto, D. N. Buell, W. W. Hope, and T. J. Walsh. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin. Pharmacol. Ther. 87:93-99.
3. Benjamin, D. K., Jr., P. B. Smith, A. Arrieta, L. G. Castro, P. J. Sanchez, D. Kaufman, L. J. Arnold, L. L. Kovanda, T. Sawamoto, D. N. Buell, W. W. Hope, and T. J. Walsh. 2010. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin. Pharmacol. Ther. 87:93-99.
4. Benjamin, D. K., Jr., B. J. Stoll, A. A. Fanaroff, S. A. McDonald, W. Oh, R. D. Higgins, S. Duara, K. Poole, A. Laptook, and R. Goldberg. 2006. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 117:84-92. (Pubitemid 46050523)
5. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.esc.edu/.
6. D'Argenio, D. Z., A. Schumitzky, and X. Wang. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
7. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
8. Drusano, G. L., A. Forrest, M. J. Snyder, M. D. Reed, and J. L. Blumer. 1988. An evaluation of optimal sampling strategy and adaptive study design. Clin. Pharmacol. Ther. 44:232-238.
9. Groll, A. H., G. Jaeger, A. Allendorf, G. Herrmann, R. Schloesser, and V. von Loewenich. 1998. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin. Infect. Dis. 27:437-452.
10. Gumbo, T., J. Hiemenz, L. Ma, J. J. Keirns, D. N. Buell, and G. L. Drusano. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331.
11. Heresi, G. P., D. R. Gerstmann, M. D. Reed, J. N. van den Anker, J. L. Blumer, L. Kovanda, J. J. Keirns, D. N. Buell, and G. L. Kearns. 2006. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J. 25:1110-1115.
12. Hope, W. W., D. Mickiene, V. Petraitis, R. Petraitiene, A. M. Kelaher, J. E. Hughes, M. P. Cotton, J. Bacher, J. J. Keirns, D. Buell, G. Heresi, D. K. Benjamin, Jr., A. H. Groll, G. L. Drusano, and T. J. Walsh. 2008. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J. Infect. Dis. 197:163-171.
13. Hope, W. W., N. L. Seibel, C. L. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J. J. Keirns, D. N. Buell, T. Gumbo, G. L. Drusano, and T. J. Walsh. 2007. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 51:3714-3719.
14. Hope, W. W., P. B. Smith, D. N. Buell, M. Roy, T. J. Walsh, M. Cohen- Wolkowiez, and D. K. Benjamin, Jr. 2009. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A1-585.
15. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
16. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, R. N. Jones, J. Turnidge, and D. J. Diekema. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
17. Seibel, N. L., C. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J. Keirns, W. M. Lau, D. P. Facklam, D. N. Buell, and T. J. Walsh. 2005. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother. 49:3317-3324.
18. Smith, P. B., T. J. Walsh, W. Hope, A. Arrieta, A. Takada, L. L. Kovanda, G. L. Kearns, D. Kaufman, T. Sawamoto, D. N. Buell, and D. K. Benjamin, Jr. 2009. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr. Infect. Dis. J. 28:412-415.
19. Tam, V. H., S. L. Preston, and G. L. Drusano. 2003. Optimal sampling schedule design for populations of patients. Antimicrob. Agents Chemother. 47:2888-2891.
20. West, G. B., J. H. Brown, and B. J. Enquist. 2000. The origin of universal scaling laws in biology, p. 87-112. In J. H. Brown and G. B. West, Scaling in biology. Oxford University Press, Oxford, United Kingdom.
21. Würthwein, G., A. H. Groll, G. Hempel, F. C. Adler-Shohet, J. M. Lieberman, and T. J. Walsh. 2005. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob. Agents Chemother. 49:5092-5098.